 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
2010 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bambang Adiwijaya (1), Joshua Henshaw (1), Maria Rosario (1), Holly Kimko (2), Varun Garg (1) | Applications of Discrete-Event Dynamic Simulation in HCV Treatment Dynamics | 3/12/2010 9:43:17 PM | Poster: Applications- Anti-infectives |
Hesham S Al-Sallami(1), Michael A Barras(2), Bruce Green(3), Stephen B Duffull(1) | A rationale for the routine monitoring of anti-activated factor X (anti-Xa) during enoxaparin treatment | 3/15/2010 2:59:27 AM | Poster: Applications- Coagulation |
Leveraging biomarker exposure-response in drug development | 3/12/2010 2:06:00 PM | Poster: Applications- Other topics | |
Anderson JM (1,2,3) Petersson KJ (3) Friberg LE (3) Worek F (4), Thiermann H (4), Buckley NA (1,2). | PK modelling of organophosphorus poisoning in humans | 3/15/2010 6:05:36 PM | Poster: Applications- Other topics |
Physiologically Based Pharmacokinetic (PBPK) Modeling of Midazolam Disposition in Pregnant and Postpartum Women | 3/12/2010 5:06:07 PM | Poster: Methodology- PBPK | |
Neil J Attkins(1), Simeon Ramsey(2), Rebecca Fish(2), Piet H. van der Graaf(1) | Model based analysis of antagonist binding kinetics at CRF-1 receptors in vitro and in vivo | 3/12/2010 4:08:51 PM | Poster: Applications- CNS |
N. Azzopardi, T. Lecomte, D. Ternant, Piller F, M. Ohresser, H. Watier, E. Gamelin, G. Paintaud | Pharmacokinetics and concentration-effect relationship of cetuximab in metastatic colorectal cancer | 3/15/2010 9:04:14 PM | Poster: Applications- Oncology |
B Jayaraman, E. Dombrowsky, D. Marsteller, Julia Winkler and J.S. Barrett | A SAS-based Solution for NONMEM run management and post-processing | 3/14/2010 8:08:33 PM | Poster: Methodology- Algorithms |
Enhancing Methotrexate Pharmacotherapy in Children with Cancer: A Decision Support System Integrating Real-time PK/PD Modeling and Simulation with Patient Medical Records | 3/14/2010 4:44:34 PM | Oral Presentation: Other topics | |
Informativeness of Internal and External Validation Techniques in Various Simulation Settings | 3/15/2010 9:36:40 PM | Poster: Methodology- Model evaluation | |
Design evaluation and optimisation in multi-response nonlinear mixed effect models with cost functions: application to the pharmacokinetics of zidovudine and its active metabolite | 3/1/2010 11:28:15 AM | Oral Presentation : Lewis Sheiner Student Session | |
Caroline Bazzoli, Anne Dubois, Thu-Thuy Nguyen, France Mentré | New features for population design evaluation and optimisation using PFIM3.2: illustration on warfarin pharmacokinetics - pharmacodynamics | 3/12/2010 1:38:57 PM | Poster: Methodology- Design |
Simulation Methodology for Quantitative Study Decision Making in a Dose Response Setting | 3/12/2010 6:47:51 PM | Poster: Methodology- Other topics | |
Semi-mechanistic modeling of absorption from extended release formulations - linking in vitro to in vivo | 3/15/2010 4:22:13 PM | Oral presentation: Physiology-based modelling | |
J. Bertrand (1), C.M. Laffont (2), E. Comets (1), M. Chenel (3), F. Mentré (1) | Genetic effect on a complex parent-metabolite joint PK model developed with NONMEM and MONOLIX | 3/15/2010 11:40:17 AM | Poster: Methodology- Other topics |
Multinomial logistic functions in Markov-chain models for modeling sleep architecture: external validation and covariate analysis | 3/15/2010 7:04:38 PM | Poster: Methodology- Model evaluation | |
PK-PD modeling of Wake after Sleep Onset time-course | 3/18/2010 5:25:40 PM | Poster: Methodology- Model evaluation | |
Mezzalana E (1), Bizzotto R (1), Sparacino G (1), Zamuner S (2) | Multinomial logistic functions in Markov-chain models for modeling sleep architecture: internal validation based on VPCs | 3/15/2010 7:18:19 PM | Poster: Methodology- Model evaluation |
Modeling of Pain Intensity Measured on a Visual Analogue Scale and Informative Dropout in a Dental Pain Model after Naproxcinod and Naproxen Administration | 3/4/2010 8:36:21 AM | Poster: Applications- CNS | |
M.A. Boroujerdi (1), A. Facius (2), M. Danhof (1), O.E. Della Pasqua (1,3) | Joint model for dropout in longitudinal trials in COPD patients | 3/15/2010 1:34:32 PM | Poster: Applications- Other topics |
Imputation of missing variance data comparing Bayesian and Classical non- linear mixed effect modelling to enable a precision weighted meta-analysis. | 3/15/2010 2:13:17 PM | Poster: Methodology- Other topics | |
Trial predictions vs. trial simulations in early clinical development: a framework to evaluate the predictive probability of success based on NONMEM outputs | 3/14/2010 9:11:57 PM | Oral Presentation: Methodology | |
Karl Brendel, Clare Gaynor, Cyrielle Dumont, Alexia Blesius and Marylore Chenel | Using Modelling & Simulation techniques to optimise the design of a paediatric PK/PD study | 2/24/2010 4:26:29 PM | Poster: Applications- Other topics |
Population pharmacokinetics-pharmacodynamics modeling of the QTc prolongation of Moxiflovoxacin and Levofloxacin in healthy volunteers: selection of the positive control in mandatory QT/QTc studies | 2/24/2010 4:33:18 PM | Poster: Applications- Other topics | |
Transit Compartment Model Useful for Describing Absorption of Quetiapine XR and IR | 1/15/2010 3:07:07 PM | Poster: Applications- CNS | |
Jürgen B. Bulitta (1), Ayhan Bingölbali (1), Cornelia B. Landersdorfer (1) | Development and Evaluation of a New Efficiency Tool (SADAPT-TRAN) for Model Creation, Debugging, Evaluation, and Automated Plotting using Parallelized S-ADAPT, Perl and R | 3/15/2010 9:37:13 PM | Software demonstration |
Mechanism-based Modelling of the Synergy of Colistin Combinations against Multidrug-Resistant Gram Negative Bacteria | 3/15/2010 10:15:14 PM | Poster: Applications- Anti-infectives | |
Integration of preclinical data to support the design of the first in-man study of LY2181308, a second generation antisense oligonucleotide. | 3/12/2010 4:59:41 PM | Poster: Applications- Other topics | |
Not-in trial simulation : Prospective use of Not-In-Trial Simulation | 3/12/2010 4:16:40 PM | Poster: Applications- CVS | |
Mechanistic Models to Simulate Dose Response of IgE Suppression Following Dosing of Anti-IgE Monoclonal Antibodies | 3/15/2010 10:58:47 AM | Oral presentation: Physiology-based modelling | |
Test Of Concept By Simulation: Comparing Response-Rate Findings Between Parallel And Titration Designs | 3/15/2010 7:42:15 PM | Poster: Methodology- Design | |
Optimal design and QT-prolongation detection in oncology studies | 2/24/2010 4:40:20 PM | Poster: Methodology- Design | |
Population Pharmacokinetics of Lurasidone in Healthy Subjects and Subjects with Schizophrenia | 3/10/2010 8:53:28 PM | Poster: Applications- CNS | |
K. Claaßen (1), S. Willmann (2), K. Thelen (3), K. Coboeken (2), K. Allegaert (4), J. Lippert (2) | Physiology-based Simulations of Amikacin Pharmacokinetics in Preterm Neonates | 3/15/2010 4:57:39 PM | Poster: Methodology- PBPK |
Colomban O. (1)(2), Naudet B. (3), Maucort-Boulch D. (3), Roy P. (3), Girard P. (2) | Toxicogenomic dose-response models for DNA chips data from rats treated by flutamide | 3/15/2010 4:31:30 PM | Poster: Methodology- Other topics |
Using simulations-based metrics to detect model misspecifications | 3/15/2010 3:30:54 PM | Poster: Methodology- Model evaluation | |
A new solution to deal with eta-shrinkage: the Weighted EBEs! | 3/15/2010 5:35:57 PM | Poster: Methodology- Model evaluation | |
Prediction of Torsades de Pointes from QT interval: analysis of a case series with amisulpride | 3/14/2010 11:37:16 PM | Poster: Applications- CVS | |
Eugène Cox (1), D. Russell Wada (1), Nancy Zhang (1) & Frank Wiegand (2) | Meta- Analysis of Retention Rates of Post-Marketing Trials to Compare Effectiveness of Second Generation Antiepileptic Drugs | 3/15/2010 8:10:31 AM | Oral presentation: Integration of literature data |
R.F.W. De Cock1, M. Danhof1, K. Allegaert2, M. de Hoog3, C.A.J. Knibbe1,3,4 | Predicting glomerular filtration rate using clearance of amikacin | 3/15/2010 7:58:32 PM | Poster: Applications- Other topics |
Bayesian framework applied to dose escalation studies for biologics | 3/15/2010 3:26:40 PM | Poster: Applications- Biologicals/vaccines | |
M. Delattre (1), R. Savic (2), R. Miller (3), M. O. Karlsson (4), M. Lavielle (5) | Estimation of mixed hidden Markov models with SAEM. Application to daily seizures data. | 2/23/2010 5:17:54 PM | Oral Presentation : Lewis Sheiner Student Session |
Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin in critically ill septic patients | 3/15/2010 5:28:31 PM | Poster: Applications- Anti-infectives | |
Application of systems pharmacology modeling approach to optimize Interferon therapy of hepatitis C | 3/13/2010 2:57:29 PM | Poster: Applications- Anti-infectives | |
Can systems modeling approach be used to understand complex PK-PD relationships? A case study of 5-lipoxygenase inhibition by zileuton | 3/12/2010 11:28:06 AM | Poster: Applications- Other topics | |
A Mechanism Based Population Pharmacokinetic-Pharmacodynamic Model for Epoetin Alfa and Darbepoetin Alfa in Chronic Kidney Disease Patients | 5/25/2010 8:35:30 AM | Poster: Applications- Biologicals/vaccines | |
Parallel first order and mixed order elimination of pyrazinamide in South African patients with tuberculosis | 6/2/2010 2:32:24 PM | Poster: Applications- Anti-infectives | |
Modelling pre-dose concentrations in steady-state data. The importance of accounting for between-occasion variability and poor adherence. | 3/15/2010 5:20:14 PM | Poster: Methodology- Other topics | |
Impact of Seizures and Efflux Mechanisms on the Biophase Kinetics and CNS Effects of Anticonvulsant Drugs | 3/15/2010 7:22:17 PM | Poster: Applications- CNS | |
Evaluation of a Method to Better Predict Human Absorption from Non-Clinical Data; Comparison of an in silico approach with population modelling of in vivo data | 3/15/2010 3:09:23 PM | Poster: Methodology- Other topics | |
A comparison of sequential and joint fitting of pain intensity and dropout hazard in acute pain studies | 3/15/2010 3:03:51 PM | Poster: Methodology- Model evaluation | |
Sufficiently high observation density justifies a sequential modeling approach of PKPD and dropout data | 3/15/2010 3:05:50 PM | Poster: Methodology- Model evaluation | |
Fractional kinetics in multi-compartmental systems | 3/5/2010 3:56:25 PM | Poster: Methodology- Other topics | |
T.P.C. Dorlo(1,2), P.J. de Vries(1), J.H. Beijnen(2) and A.D.R. Huitema(2) | Optimal Dosing of Miltefosine in Children and Adults with Leishmaniasis | 3/14/2010 11:10:26 PM | Poster: Applications- Anti-infectives |
Pharmacokinetic/Pharmacodynamic Modeling of Platinum-DNA-Adduct Formation in Leukocytes after Oxaliplatin Infusion | 3/15/2010 4:22:14 PM | Poster: Applications- Oncology | |
Pinky Dua(1), Nicoletta Pons(2), Luigina Bertolotti(2), Clare Burgess(3), Roberto Gomeni(1) | SB-773812: Correlation between in-silico and in-vivo metabolism | 3/8/2010 6:21:27 PM | Poster: Applications- Other topics |
A. Dubois (1), S. Gsteiger (2), E. Pigeolet (2) and F. Mentré (1) | Model-based bioequivalence analysis of pharmacokinetic crossover trials compared to standard non-compartmental analysis | 3/15/2010 10:12:00 AM | Poster: Methodology- Other topics |
Anne Dubois (1), Sigrid Balser (2), Sandro Gsteiger (3), Etienne Pigeolet (3) and France Mentré (1) | Model-based bioequivalence analysis of recombinant human growth hormone using the SAEM algorithm: liquid or lyophilized formulations of Omnitrope® versus original lyophilized Genotropin® | 3/15/2010 10:09:21 AM | Poster: Applications- Other topics |
Translation of drug-induced QTc prolongation in early drug development. | 3/15/2010 11:07:24 AM | Poster: Applications- CVS | |
Derivation of SAEM C-matrix in Phoenix | 3/13/2010 7:37:15 PM | Poster: Methodology- Algorithms | |
Allometric scaling in oncology disease progression from xenograft tumor growth to human non-small-cell lung cancer | 3/15/2010 8:47:01 PM | Poster: Applications- Oncology | |
Predictor Identification in Time-to-Event Analyses | 3/15/2010 1:35:55 PM | Poster: Methodology- Other topics | |
Bronchial Allergen Challenge in Asthma: A Model for Inhaled Corticosteroids (ICS) and Montelukast using Literature Summary Data | 3/13/2010 12:47:45 AM | Poster: Methodology- Other topics | |
Analysis of Adverse Events using Literature Data: a Simulation Study | 3/12/2010 11:58:04 PM | Poster: Methodology- Other topics | |
Modeling Adverse Event rates of Opioids for the Treatment of Osteoarthritis Pain using Literature Data | 3/13/2010 1:14:38 AM | Poster: Methodology- Other topics | |
Population PK/PD model of the sedative effects of Flibanserin in healthy volunteers | 3/15/2010 11:30:18 AM | Poster: Applications- Other topics | |
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies using diflomotecan and indisulam | 3/15/2010 11:21:32 AM | Poster: Applications- Oncology | |
Phase I trials: Model-based assessment to identify a clinical relevant change in heart rate | 3/8/2010 1:40:42 PM | Poster: Applications- Other topics | |
D-optimal Adaptive Bridging Studies in Pharmacokinetics | 3/12/2010 6:49:19 AM | Oral Presentation: Methodology | |
N. Frances (1), L. Claret (2), F. Schaedeli Stark (3), R. Bruno (2), A. Iliadis (1) | Influence analysis explores heterogeneity in database before data processing by a parametric population method | 3/15/2010 7:22:56 PM | Poster: Methodology- Design |
M. Frank (1), A. Kunz (2), G. Harms (2), JS. Van der Walt (3,4), C. Kloft (1) | Population Pharmacokinetic Model Building for Mothers and Newborns using Additional Information from a Different Nevirapine Dataset | 3/15/2010 11:28:57 AM | Poster: Applications- Anti-infectives |
Martin Fransson(1), Henrik Gréen(2), Jan-Eric Litton(1), Lena E. Friberg(3) | Pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model | 3/15/2010 8:59:51 PM | Poster: Applications- Oncology |
When and how should I combine patient-level data and literature data in a meta-analysis? | 5/24/2010 9:25:23 PM | Oral presentation: Integration of literature data | |
Physiologically-Based Pharmacokinetic (PBPK) Modelling of Bisoprolol in Adults and Children and External Model Validation in a Paediatric Clinical Trial | 3/14/2010 6:15:15 PM | Poster: Applications- CVS | |
Population pharmacokinetic modelling of unbound and total plasma concentrations of oxaliplatin administered by hepatic arterial infusion to patients with liver-metastases. | 3/15/2010 12:09:10 PM | Poster: Applications- Oncology | |
Comparison of MCMC simulation results using NONMEM 7 or WinBUGS with the BUGSModelLibrary | 3/12/2010 6:08:26 PM | Poster: Methodology- Algorithms | |
Influence of cyclosporin dosing schedule on receptor occupancy in bone marrow transplantation: analysis with a PBPK-PD model | 3/15/2010 10:59:55 PM | Poster: Methodology- PBPK | |
Bias and Precision of Parameter Estimates: Comparison of Nonmem 7 Estimation Methods and PFIM 3.2 Predictions on the Example of Quasi-Steady-State Approximation of the Two-Target Target-Mediated Drug Disposition Model | 3/10/2010 6:11:43 PM | Poster: Methodology- Algorithms | |
Target-Mediated Drug Disposition: New Derivation of the Michaelis-Menten Model, and Why It Is Often Sufficient for Description of Drugs with TMDD | 3/10/2010 7:03:44 PM | Poster: Methodology- Other topics | |
TMDD Model for Drugs that Bind Soluble and Membrane-Bound Targets: Can Quasi-Steady-State Approximation Estimate Unobservable Membrane-Bound Target Occupancy? | 4/21/2010 8:13:12 PM | Poster: Methodology- Other topics | |
Evaluation of a Mechanism-Based Pharmacokinetic-Pharmacodynamic Model for D2 Receptor Occupancy of Olanzapine in Rats | 3/15/2010 10:48:25 AM | Poster: Applications- CNS | |
Integrated approach to overcome a food effect in clinical studies: an example of how in vitro, in vivo and simulation tools can help in determining an appropriate strategy | 3/12/2010 11:49:49 AM | Poster: Methodology- Other topics | |
S. Goutelle (1,2), L. Bourguignon (1,2), R.W. Jelliffe (3), J.E. Conte Jr (4,5), P. Maire (1,2) | Mathematical modeling of pulmonary tuberculosis therapy: development of a first prototype model with rifampin | 3/14/2010 1:13:26 PM | Oral Presentation: Other topics |
Continuous time Markov modelling of relapse sojourns for relapse-remitting multiple sclerosis patients | 3/15/2010 4:22:16 PM | Poster: Applications- CNS | |
Forensic Pharmacometrics: Part 2 - Deliverables for Regulatory Submission | 3/15/2010 8:04:41 PM | Poster: Methodology- Other topics | |
Forensic Pharmacometrics: Part 1 - Data Assembly | 3/15/2010 7:59:49 PM | Poster: Methodology- Other topics | |
Population Pharmacokinetic and Pharmacodynamic Meta Analysis of Zenvia: Modeling of QT Prolongation | 3/12/2010 4:38:24 PM | Poster: Methodology- Model evaluation | |
Population Pharmacokinetic Meta Analysis: Inhibition by Quinidine of the First-Pass and Systemic Metabolism of Dextromethorphan to Dextrorphan | 3/12/2010 4:34:08 PM | Poster: Methodology- Model evaluation | |
J. Guedj (1), C. Bazzoli (2), A.U. Neumann (3), F. Mentre (2) | Design Evaluation and Optimization for models of Hepatitis C viral dynamics | 3/15/2010 3:44:44 AM | Poster: Applications- Anti-infectives |
Is pharmacokinetic variability in microdosing trials comparable to variability following therapeutic doses? | 3/9/2010 11:28:59 AM | Poster: Methodology- Other topics | |
AK Hamberg (1), M Wadelius (1), M Pirmohamed (2), EN Jonsson (3)(4) | Internal and external evaluation of a K-PD model for warfarin using prediction corrected visual predictive check (PC-VPC) | 3/15/2010 9:59:47 AM | Poster: Applications- Coagulation |
Kajsa Harling, Sebastian Ueckert, Andrew C. Hooker, E. Niclas Jonsson and Mats O. Karlsson | Xpose and Perl speaks NONMEM (PsN) | 3/15/2010 3:31:07 PM | Software demonstration |
Michael Heathman (1), Donald Jennings (1), and Bernett Lee (2) | Interactive Simulation and Visualization of Drug/Disease Models | 3/9/2010 4:57:55 PM | Poster: Methodology- Other topics |
Semi-physiological modeling of absorption kinetics: application to diclofenac | 3/12/2010 3:01:16 PM | Oral presentation: Physiology-based modelling | |
A population PK model of EPA and DHA after intake in phospholipid as well as in triglyceride form. | 3/16/2010 4:05:27 PM | Poster: Applications- Other topics | |
Title: Modeling exposure-response relationships in the rat self-administration model | 3/15/2010 6:08:55 PM | Poster: Applications- CNS | |
Preliminary Population PK-PD of Dalcetrapib: an Agent Targeting CETP to Raise HDL-C and Prevent Cardiovascular Morbidity and Mortality | 3/15/2010 10:34:16 AM | Poster: Applications- CVS | |
Evaluation of a Physiologically-Based Pharmacokinetic (PBPK) Model for the Application of Low Dose Etoposide in Children | 3/15/2010 5:56:22 PM | Poster: Methodology- PBPK | |
Physiologically-based pharmacokinetic/pharmacodynamic modelling, mathematical model reduction and a mechanistic interpretation of simple empirical models | 4/19/2010 2:48:14 PM | Oral presentation: Physiology-based modelling | |
Extending the Latent Variable Model to Non-Independent Longitudinal Dichotomous Response Data | 2/17/2010 8:55:18 PM | Oral Presentation: Methodology | |
Critical illness is a major determinant for midazolam and metabolite clearance in children | 3/15/2010 11:54:08 AM | Poster: Applications- Other topics | |
A Novel PKPD Model to Describe the Interaction of Drug Response of Combination Therapy: An Application in Preclinical Oncology. | 3/15/2010 3:41:14 PM | Poster: Applications- Oncology | |
Simcyp Simulator - a comprehensive platform and database for mechanistic modelling and simulation of drug absorption, tissue distribution, metabolism, transport and elimination in healthy and disease populations using in vitro knowledge | 4/27/2010 3:50:40 PM | Software demonstration | |
Seong Bok Jang(1), Min Soo Park(2), Young Goo Song(3), Kyungsoo Park(1) | Population Pharmacokinetics of Amikacin in Korean Clinical Population | 3/15/2010 2:28:40 PM | Poster: Applications- Anti-infectives |
SimBiology: A Graphical Environment for Population PK/PD | 3/15/2010 8:37:53 PM | Software demonstration | |
Åsa M. Johansson, Sebastian Ueckert, Elodie L. Plan, Andrew C. Hooker, Mats O. Karlsson | New Estimation Methods in NONMEM 7: Evaluation of Bias and Precision | 3/15/2010 10:39:45 PM | Poster: Methodology- Algorithms |
Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients | 3/15/2010 2:30:48 PM | Poster: Applications- Anti-infectives | |
A Longitudinal Tumor Growth Inhibition Model Based on Serum M-Protein Levels in Patients With Multiple Myeloma Treated by Dexamethasone | 2/27/2010 2:41:12 PM | Poster: Applications- Oncology | |
M. Kågedal(1), Z. Cseleny(1), S. Nyberg(1), Per Karlsson (2), A Hooker(3), MO Karlsson(3) | Estimation of occupancy and radioligand kinetics in the CNS from PET-data in the absence of a reference region. | 3/12/2010 10:53:39 AM | Poster: Applications- CNS |
Kristin E. Karlsson (1), Mats O. Karlsson (1) and E. Niclas Jonsson (1)(2) | Clinical trial simulations using a stroke disease progression model | 3/15/2010 4:09:22 PM | Poster: Applications- CNS |
RJ Keizer, Y Funahashi, T Semba, J Wanders, JH Beijnen, JHM Schellens, ADR Huitema | Evaluation of clinical dosing of E7820 from preclinical and clinical data using a biomarker | 2/1/2010 5:47:35 PM | Poster: Applications- Oncology |
Piraña: Open source modeling environment for NONMEM | 2/1/2010 5:42:37 PM | Software demonstration | |
Ron J Keizer, Robert S Jansen, Hilde Rosing, Jos H Beijnen, Jan HM Schellens, Alwin DR Huitema | Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses | 3/8/2010 3:51:00 PM | Poster: Methodology- Other topics |
Population pharmacokinetic analysis of ciprofloxacin in intensive care unit adult patients | 3/15/2010 7:02:01 PM | Poster: Applications- Anti-infectives | |
You have problems to interpret VPC? Try VIPER! | 3/15/2010 7:15:23 PM | Oral Presentation: Methodology | |
Akash Khandelwal, Kajsa Harling, E Niclas Jonsson, Andrew C Hooker, Mats O Karlsson | Covariate Model Building Using Linear Approximations | 3/15/2010 11:00:31 PM | Oral presentation: Covariate model building |
Modeling & Simulation Exercise to Recommend Dosage Regimens for Patients with End-Stage Renal Disease Receiving Hemodialysis | 3/13/2010 10:03:42 PM | Poster: Applications- Anti-infectives | |
Penetration of Isoniazid, Rifampicin, Pyrazinamide and Moxifloxacin into Pulmonary TB Lesions in Rabbits | 3/15/2010 5:27:46 PM | Poster: Applications- Anti-infectives | |
W. Knebel*(1), T. Bergsma (1), C. Dagdigian (2), J. Hane (1), M. R. Gastonguay (1) | A Strategy for Efficient Implementation of NONMEM 7 and the Intel Fortran Compiler in a Distributed Computing Environment | 3/12/2010 5:34:18 PM | Poster: Methodology- Other topics |
Design of survival studies for red blood cells | 2/26/2010 3:15:44 AM | Oral presentation: Physiology-based modelling | |
Predictive performance of two PK-PD models of D2 receptor occupancy of the antipsychotics risperidone and paliperidone in rats | 3/15/2010 10:58:31 AM | Poster: Applications- CNS | |
Paracetamol pharmacokinetics in term and preterm neonates. | 3/12/2010 1:56:38 PM | Poster: Applications- Other topics | |
An Interpretation of Transit Compartment Pharmacodynamic Models As Lifespan Based Indirect Response Models. | 3/12/2010 8:56:29 PM | Poster: Methodology- PBPK | |
Brigitte D. Lacroix(1,2), Lena E. Friberg(1) and Mats O. Karlsson(1) | Evaluating the IPPSE method for PKPD analysis | 3/15/2010 3:34:42 PM | Oral Presentation: Methodology |
Simultaneous modeling of the three ACR improvement thresholds – 20, 50 and 70% - in rheumatoid arthritis patients treated with certolizumab pegol | 3/15/2010 11:06:26 AM | Poster: Methodology- Other topics | |
Pharmacodynamic (PD) Modelling of Anti-Proliferative Effects of Tetraiodothyroacetic Acid (Tetrac) on Human Cancer Cells | 3/15/2010 4:34:43 PM | Poster: Applications- Oncology | |
A. Lagajolli (1), A. Bertoldo (1), P. Denti (2), C. Cobelli (1) | Assessment of the oral glucose minimal model by nonlinear mixed-effects approaches | 3/16/2010 7:49:28 PM | Poster: Applications- Endocrine |
Analysing population PK/PD data with MONOLIX 3.2 | 3/11/2010 5:17:32 PM | Software demonstration | |
Marc Lavielle (1), Hector Mesa (1), Kaelig Chatel (1), An Vermeulen (2) | Mixture models and model mixtures with MONOLIX | 3/15/2010 4:31:29 PM | Oral Presentation: Methodology |
Maud Delattre (1), Pierre Del Moral (2), Marc Lavielle (1,3) | The SAEM algorithm in MONOLIX for Non-Linear Mixed Effects Models with Stochastic Differential Equations | 3/11/2010 3:53:33 PM | Poster: Methodology- Algorithms |
Quasi-Monte Carlo EM Methods for NLME Analysis | 3/11/2010 10:24:24 PM | Poster: Methodology- Algorithms | |
Model-based evaluation of DAS28 as a potential surrogate for ACR20 to establish the dose-response relationship for disease modifying anti-rheumatic drugs. A case study using tasocitinib (CP-690,550), an oral JAK inhibitor. | 2/27/2010 7:59:22 AM | Poster: Applications- Other topics | |
A population analysis of Intravenous Dexmedetomidine in Korean | 3/26/2010 2:14:41 AM | Poster: Applications- CNS | |
Optimization of sampling times for PK/PD models: approximation of elemental Fisher information matrix | 3/15/2010 3:17:07 AM | Poster: Methodology- Design | |
Towards Quantitative Prediction Of In Vivo Brain Penetration Using A Physiology Based CNS Disposition Model | 2/16/2010 4:35:40 PM | Poster: Applications- CNS | |
Population PK-PD modeling of thorough QT/QTc data allows for mechanistic understanding of observed QTc effects | 3/12/2010 4:31:50 PM | Poster: Methodology- Other topics | |
Dose-Response-Dropout Analysis for Somnolence in Pregabalin-treated Patients with Generalized Anxiety Disorder | 2/27/2010 4:27:23 AM | Oral Presentation : Lewis Sheiner Student Session | |
Mechanistic analysis of fusion proteins: PBPK applied in an Albuferon case study | 3/15/2010 5:15:07 PM | Poster: Methodology- PBPK | |
Simulation of the pharmacokinetics of flibanserin under itraconazole co-mediaction with an integrated physiologically-based pharmacokinetic model | 3/15/2010 5:24:04 PM | Poster: Methodology- PBPK | |
Identifying cancer drug MoAs and cell-line properties using signaling cascade models and Bayesian analysis: From throw-away experiments to persistent information | 3/15/2010 4:56:53 PM | Poster: Methodology- PBPK | |
M. Meyer (1), S. Willmann (1), C. Becker (2), R. Burghaus (2), W. Mueck (2), J. Lippert (1) | Influence of CYP1A1 induction by cigarette smoke on pharmacokinetics of erlotinib: a computer-based evaluation of smoke-induced CYP1A1 activity in different tissues | 3/15/2010 5:23:16 PM | Poster: Methodology- PBPK |
Clinical trial simulation with multiscale models: Integrating whole-body physiology, disease biology, and molecular reaction networks | 3/15/2010 5:09:52 PM | Poster: Methodology- PBPK | |
M. Meyer, L. Kuepfer, D. Chandra Prakash, S. Schneckener, B. Ludewig, J. Lippert | Using relative gene expression measurements for PBPK modeling of pravastatin | 3/15/2010 5:18:47 PM | Poster: Methodology- PBPK |
Michael Block, Linus Görlitz, Clara Happ, Rolf Burghaus, Jörg Lippert | Separating individual physiological variability from drug related properties using PBPK Modeling with PK-Sim® and MoBi® – Theophylline | 3/15/2010 5:02:29 PM | Poster: Methodology- PBPK |
Rocío Lledó-García, PhD1, Norman A. Mazer, MD, PhD2 and Mats O. Karlsson, PhD1 | A mechanistic model of the steady-state relationship between HbA1c and average glucose levels in a mixed population of healthy volunteers and diabetic subjects | 3/14/2010 9:50:13 PM | Oral presentation: Integration of literature data |
The Development of a Link Model Consisting of in vitro Drug Release and Tablets Gastric Emptying Time: Application to Diclofenac Enteric Coated Tablets | 3/15/2010 11:08:24 PM | Poster: Methodology- Other topics | |
Modeling and Simulation of Drug X and its Metabolite in Plasma and Urine | 1/15/2010 3:29:30 PM | Poster: Methodology- Model evaluation | |
A Mechanistic Approach to Predicting Human Pharmacokinetics of Monoclonal Antibodies from Preclinical Data: A Case Example | 3/15/2010 7:02:03 PM | Poster: Applications- Biologicals/vaccines | |
Thuy Vu, Edward Lee, Naren Narayanan, Graham Jang, and Peiming Ma | Predicting Free Sclerostin from Free AMG 785 and Total Sclerostin | 4/13/2010 6:23:38 PM | Poster: Applications- Biologicals/vaccines |
H. Marouani (1), L. Claret (2), C. Faivre (1), A. Iliadis (1) | Nonparametric Approach using Gaussian Kernels Estimates Multivariate Probability Densities in Population Pharmacokinetics | 3/12/2010 7:34:51 PM | Poster: Methodology- Algorithms |
PKPD Modeling of Dose-Response & Time Course of B-Cell Depletion in Cynomolgus Monkeys | 3/12/2010 6:52:13 PM | Poster: Applications- Other topics | |
Sarah C McLeay (1), Glynn A Morrish (1), Carl MJ Kirkpatrick (1) & Bruce Green (2) | Exploring different body-size metric based dosing strategies for propofol in morbidly obese versus healthy weight subjects by modelling and simulation approach | 3/14/2010 11:37:33 AM | Oral presentation: Integration of literature data |
Circulator Is a New Technique for Systems Pharmacology | 3/15/2010 11:31:44 AM | Poster: Methodology- Other topics | |
Evaluation of disease covariates in chronic obstructive pulmonary disease (COPD). | 3/15/2010 5:13:25 PM | Poster: Methodology- Design | |
An optimal designed study for population pharmacokinetic modeling and Bayesian estimation of Mycophenolic acid and Tacrolimus early after renal transplantation | 3/16/2010 2:35:36 AM | Poster: Applications- Other topics | |
N. Jebabli, H. El jebari, E. Gaïes, I. Salouage, S.Trabelsi, M. Lakhal, A. Klouz | Population Pharmacokinetics Of Vancomycin In Tunisian Patients | 3/13/2010 12:58:14 PM | Poster: Applications- Anti-infectives |
N. Jebabli, I. Salouage, S.Trabelsi, E. Gaïes, H. El jebari, Ch. Belkahia, M. Lakhal, A. Klouz | Pharmacokinetic Modelling Of Methotrexate From Routine Clinical Data In Patients With Acute Lymphoblastic Leukemia | 3/3/2010 11:18:38 AM | Poster: Applications- Oncology |
H. Eljebari, N. Jebabli, S. Trabelssi, I. Salouage , E. Gaies, M. Lakhal, A. Klouz | Effect Of Clonidine On Bupivacaine Clearance In Tunisian Patients: Population Pharmacokinetic Investigation. | 3/8/2010 12:41:15 PM | Poster: Applications- Other topics |
Bioequivalence trials simulation to select the best analyte for drugs with two metabolic pathways | 3/15/2010 12:00:20 PM | Poster: Methodology- Other topics | |
The MM-USCPACK software for nonparametric adaptive grid (NPAG) population PK/PD modeling, and the MM-USCPACK clinical software for individualized drug regimens. | 4/12/2010 12:25:12 PM | Software demonstration | |
Pharmacogenomics and Individualized Dosage Regimens | 4/12/2010 12:26:27 PM | Poster: Applications- Other topics | |
High-dose amoxicillin pharmacokinetics (PK) and pharmacodynamics (PD) in children | 3/15/2010 9:54:48 AM | Poster: Applications- Anti-infectives | |
Design evaluation and optimisation in crossover pharmacokinetic studies analyzed by nonlinear mixed effects models | 3/12/2010 11:21:40 AM | Poster: Methodology- Design | |
Population pharmacokinetic of linezolid in inpatients | 3/12/2010 10:23:19 AM | Poster: Applications- Anti-infectives | |
R. Niebecker (1,2), K. Kuester (1), U. Kunz (3), C. Kloft (1) | Impact of Different Body Size Descriptors on the Population Pharmacokinetics of a Monoclonal Antibody | 5/21/2010 1:35:15 PM | Poster: Applications- Biologicals/vaccines |
Pharmacokinetic-Pharmacodynamic Modelling for Antibiotics: Static and Dynamic In Vitro Time-Kill Curve Experiments | 3/15/2010 10:34:08 AM | Poster: Applications- Anti-infectives | |
V. Nock (1, 2), A. Lindauer (3), U. Jaehde (3), C. Kloft (1) | Leukopenia following high-dose chemotherapy with autologous stem cell retransfusion in patients with testicular cell cancer | 3/15/2010 1:41:39 PM | Poster: Applications- Oncology |
Joakim Nyberg, Sebastian Ueckert, Mats O. Karlsson, Andrew C. Hooker | Global, exact and fast group size optimization with corresponding efficiency translation in optimal design | 3/15/2010 5:50:00 PM | Poster: Methodology- Design |
Investigations of the weighted residuals in NONMEM 7 | 3/15/2010 6:07:39 PM | Poster: Methodology- Model evaluation | |
A true Markov model for sleep disturbance | 3/15/2010 1:07:39 PM | Poster: Methodology- Other topics | |
Nonlinear Pharmacokinetic Model For Interleukin-12 Gene Therapy | 3/15/2010 7:51:51 PM | Poster: Methodology- PBPK | |
Estimation of Individual Parameters of a Mixed–Effects Dose-Toxicity Model for Ordinal Data | 3/14/2010 11:22:07 PM | Poster: Methodology- Algorithms | |
Bayesian POP-PK analysis of exposure data from a Phase IIb clinical trial | 3/15/2010 4:23:59 PM | Poster: Methodology- Other topics | |
Predictions of in vivo prolactin levels from in vitro Ki values of D2 receptor antagonists using an agonist-antagonist interaction model. | 3/1/2010 9:05:24 PM | Oral Presentation: Clinical Applications | |
The Influence Of Covariate Distribution On The Prediction And Extrapolation Of Pharmacokinetic Data In Children. | 3/15/2010 7:48:19 PM | Poster: Methodology- Model evaluation | |
C. Piana(1), K. Adkinson(2), M. Danhof(1), , O.E. Della Pasqua(1,3) | Once Daily Pharmacokinetics Of Lamivudine In HIV-Infected Children | 3/15/2010 7:38:46 PM | Poster: Applications- Other topics |
Lumping of Physiologically Based Pharmacokinetic Models and a Mechanistic Derivation of Classical Compartmental Models | 3/16/2010 10:55:26 AM | Poster: Methodology- PBPK | |
Modeling and Simulation of Placebo Response and Dropout Patterns in Treatment of Schizophrenia | 3/14/2010 11:38:22 PM | Poster: Applications- CNS | |
Elodie L. Plan (1), Alan Maloney (1,2), France Mentré (3), Mats O. Karlsson (1), Julie Bertrand (3) | Nonlinear Mixed Effects Estimation Algorithms: A Performance Comparison for Continuous Pharmacodynamic Population Models | 3/15/2010 5:52:15 PM | Poster: Methodology- Algorithms |
Analysis Approaches Handling Both Symptomatic Severity and Frequency | 3/1/2010 5:13:04 PM | Oral Presentation: Methodology | |
Laura Iavarone, Marianna Machin, Marta Neve, Roberto Gomeni, Stefano Zamuner, Italo Poggesi | Modeling a time-dependent absorption constant: a trick and some considerations | 3/15/2010 4:35:32 PM | Poster: Methodology- Model evaluation |
Angelica L. Quartino (1), Joakim Nyberg (1), Marie Cullberg (2), Lena E. Friberg (1) | Application of Optimal Design to Reduce the Sample Costs of a Dose-finding Study | 3/15/2010 5:44:14 PM | Poster: Methodology- Design |
Ramusovic, S.(1), Willmann, S.(2), Frobel, A.-K.(1), Laeer, S.(1) | An integrated whole-body physiology based pharmacokinetic/pharmacodynamic model of enalapril and the RAA-system | 3/15/2010 5:14:19 PM | Poster: Applications- CVS |
A trial simulation example to support the design and model-based analysis of a new dose and regimen finding study | 3/5/2010 11:42:33 AM | Poster: Applications- Other topics | |
Bayesian modeling of a PK-PD relationship to support an adaptive dose-finding trial | 3/15/2010 1:02:52 PM | Poster: Methodology- Design | |
Ribba B,, Watkin E., Tod M., Girard P., Grenier E., You B., Wei M., Giraudo E., Freyer G. | Combined analysis of tumor size data and histological biomarkers drives the development of a semi-mechanistic model of the effect of the antiangiogenic drug Sunitinib in mice | 3/15/2010 9:42:49 AM | Poster: Applications- Oncology |
Elba M. Romero Tejeda, Nieves Vélez de Mendizábal, Iñaki F. Trocóniz | Development of a mechanistic-based pharmacodynamic model to describe the effect of a prolonged administration of a GnRH agonist on testosterone levels | 3/15/2010 10:35:33 PM | Poster: Applications- Endocrine |
Rühs H(1), Panetta JC(2), Pui CH(2), Relling MV(2), Jaehde U(1) | Homocysteine as biomarker in a semi-mechanistic PK/PD model of methotrexate | 3/15/2010 8:49:13 PM | Poster: Applications- Oncology |
Integrated model for clinical response and dropout in depression trials: a state-space approach | 3/15/2010 4:31:04 PM | Oral Presentation: Methodology | |
Tarjinder Sahota (1), Nuria Buil (2), Katsutoshi Hara (2), Oscar Della Pasqua (1,2) | The Chicken and the Egg in Interoccasion Variability | 3/15/2010 6:35:04 PM | Poster: Methodology- Other topics |
Tarjinder Sahota (1), Meindert Danhof (1), Oscar Della-Pasqua (1,2) | Model-based safety thresholds for discrete adverse events | 3/15/2010 6:31:51 PM | Poster: Methodology- Other topics |
Switching to Paliperidone Palmitate[1,2] from Other Depot Antipsychotics: Guidance Based on Pharmacokinetic Simulations | 3/15/2010 3:11:38 PM | Poster: Applications- CNS | |
Adherence and Population Pharmacokinetics of Atazanavir in Naïve HIV-Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing | 3/15/2010 5:58:54 AM | Oral Presentation: Clinical Applications | |
Ciprofloxacin Integrated Plasma, Saliva and Sweat Population Pharmacokinetics and Emergence of Resistance in Human Commensal Bacteria | 3/15/2010 5:07:10 AM | Poster: Applications- Anti-infectives | |
Implication of differences in model parameterisation in osteoporosis | 3/15/2010 9:20:05 AM | Poster: Methodology- Model evaluation | |
Some considerations concerning covariates in clinical trials | 4/12/2010 8:29:53 AM | Tutorial | |
Disease System Analysis: Evaluate the structural properties and the physiological implications of an indirect physiologic response model describing the degenerative progression of Alzheimer’s disease using a closed-form solution | 2/16/2010 6:35:59 PM | Poster: Applications- CNS | |
Clinical and Genetic factors affecting Alzheimer’s disease progression in subjects on stable acetylcholinesterase inhibitor therapy: a comparison between mechanistic and empirical disease progression modelling approaches | 2/1/2010 12:32:17 PM | Poster: Applications- CNS | |
An R package for industrializing concentration-QT analysis | 3/14/2010 12:41:15 PM | Poster: Methodology- Other topics | |
W Smythe(1), H McIlleron(1), C Merle (2), J Horton(3), P Smith(1), and USH Simonsson(4) | A Semi-Mechanistic pharmacokinetic enzyme model for the characterisation of rifampicin pharmacokinetics in South African pulmonary tuberculosis infected adults | 3/12/2010 11:00:06 AM | Poster: Applications- Anti-infectives |
Modelling the interaction between Irinotecan and efflux transporters inhibitors: A KPD tumour growth inhibition model including interaction components. | 2/28/2010 6:53:41 PM | Poster: Applications- Oncology | |
Exposure-response modeling of daily seizure counts in focal epilepsy trials | 3/10/2010 11:20:48 AM | Poster: Applications- CNS | |
Analysis of Biomarker Responses in Phase I Study of rhIL-18 in Combination with Rituximab in Non-Hodgkin’s Lymphoma to Support Phase 2 Dose Selection | 3/15/2010 2:27:39 PM | Poster: Applications- Oncology | |
A. Mohamed (1), E.I. Nielsen (1), O. Cars (2) and L.E. Friberg (1). | Predictions of Dosing Schedules of Gentamicin in Neonates Based on a Pharmacokinetic/Pharmacodynamic Model Considering Adaptive Resistance | 3/15/2010 5:41:54 PM | Poster: Applications- Anti-infectives |
Optimisation of experimental design for drug screening in behavioural models of pain. | 3/15/2010 8:53:16 PM | Poster: Methodology- Design | |
Population pharmacokinetics of antimalarial drugs in the treatment of pregnant women with uncomplicated malaria | 3/15/2010 5:49:21 PM | Poster: Applications- Anti-infectives | |
Methotrexate influences neither pharmacokinetics nor concentration-effect relationship of infliximab in axial ankylosing spondylitis | 2/26/2010 7:26:08 PM | Poster: Applications- Biologicals/vaccines | |
Development of a template for clinical trial simulations in COPD | 3/15/2010 5:38:58 PM | Poster: Methodology- Design | |
A mechanism-based model for the population pharmacokinetics of aflibercept in healthy subjects | 3/15/2010 1:58:21 PM | Poster: Applications- Oncology | |
Population Pharmacokinetics of Safinamide and its Effect on Disease Progression in Parkinson's Disease | 3/15/2010 1:55:04 PM | Poster: Applications- CNS | |
K. Thelen (1), K. Coboeken (2), S. Willmann (2), J.B. Dressman (1), J. Lippert (2) | A novel physiological model to simulate gastrointestinal fluid dynamics, transit of luminal contents, absorption, and pre-systemic metabolism of orally administered drugs in humans | 3/15/2010 4:51:08 PM | Poster: Methodology- PBPK |
Trame MN(1), Bartelink IH(2), Boos J(3), Boelens JJ(2), Hempel G(1,3) | External Evaluation of a Population Pharmacokinetic Model for Dosing Busulfan in Children – Body Surface Area better than Body Weight | 3/15/2010 8:47:25 PM | Poster: Applications- Oncology |
Xiaoyun Li, Andrew Lewandowski, Huafeng Zhou, A. Lawrence Gould, Kuenhi Tsai | Estimation Comparison of Pharmacokinetic Models Using MONOLIX, PKBUGS, and NONMEM | 2/25/2010 9:02:11 PM | Poster: Methodology- Other topics |
Cyclophosphamide, Methotrexate, and 5-Fluorouracil Population Pharmacokinetic Models with Pharmacogenetic Covariates | 3/11/2010 1:17:39 PM | Poster: Applications- Oncology | |
Joakim Nyberg, Sebastian Ueckert, Mats O. Karlsson and Andrew C. Hooker | PopED - An optimal experimental design software | 3/15/2010 10:18:48 PM | Software demonstration |
Comparison of Different Global Optimal Design Approximations | 3/15/2010 10:26:59 PM | Poster: Methodology- Design | |
Sebastian Ueckert, Åsa M. Johansson, Elodie L. Plan, Andrew Hooker, Mats O. Karlsson | New Estimation Methods in NONMEM 7: Evaluation of Robustness and Runtimes | 3/15/2010 9:19:56 PM | Poster: Methodology- Algorithms |
Generalisation of T-optimality for discriminating between competing models - an application to paracetamol overdose | 3/12/2010 3:03:53 AM | Poster: Methodology- Design | |
Plasma and Cerebrospinal Fluid Pharmacokinetics of Naproxen in Children | 3/15/2010 8:59:33 AM | Poster: Applications- CNS | |
Optimal dosing of lidocaine for seizure control in preterm and term neonates using population pharmacokinetic modelling and simulation | 2/25/2010 1:18:52 PM | Poster: Applications- CNS | |
A population model describing the pharmacokinetics of iv esomeprazole in patients aged 0 to 17 years, inclusive | 3/15/2010 8:16:16 PM | Poster: Applications- Other topics | |
J. G. Coen van Hasselt (1), Bruce Green (2), Glynn A. Morrish (3) | Application of a semi-physiological model describing time-varying pharmacokinetics to support optimal clinical study design | 3/12/2010 9:29:00 AM | Poster: Methodology- Design |
J. G. Coen van Hasselt (1,2), Ron J. Keizer (1,2), M. van Benten (3), Alwin D. R. Huitema (1,2) | Implementation of an affordable computing cluster for pharmacometric analysis | 3/8/2010 2:50:09 PM | Poster: Methodology- Other topics |
Stephane Vellay, Guillaume Paillard, Eddy Vande Water, Richard Compton | Pipeline Pilot - Data Integration, Analysis, and Reporting Platform | 1/15/2010 8:36:30 AM | Software demonstration |
F. Verga (1) (2), B. You (3), A. Benabdallah (2), F. Hubert (2), C Faivre (1), D. Barbolosi (1) | Modeling of the metastatic variability in cancer disease. | 3/12/2010 4:25:48 PM | Poster: Applications- Oncology |
Anders Viberg (1), John Martino (2), Etienne Lessard (2) and Jennifer Laird (2) | Using an Innovative Design in Behavioural Pharmacology Studies Saves Money and Animal Lives | 3/15/2010 8:08:23 PM | Poster: Applications- CNS |
Rapid sample size calculations for a defined likelihood ratio test-based power in mixed effects models | 3/15/2010 5:12:41 PM | Oral Presentation: Methodology | |
Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling for Integrase Inhibitors with a Simple Viral Dynamic Model | 3/15/2010 2:35:50 AM | Poster: Applications- Anti-infectives | |
Internal and external validation with sparse, adaptive-design data for evaluating the predictive performance of a population pharmacokinetic model of tacrolimus | 3/15/2010 4:30:58 PM | Poster: Applications- Other topics | |
Scaling clearance of propofol from preterm neonates to adults using an allometric model with a bodyweight-dependent maturational exponent | 3/15/2010 11:53:17 AM | Poster: Applications- Other topics | |
A Pharmacokinetic Study of Ranitidine in a Paediatric Population | 3/15/2010 6:34:31 PM | Poster: Methodology- Other topics | |
Paweł Wiczling (1), Michael Rosenzweig (2), Louis Vaickus (2), and William J. Jusko (3) | Pharmacokinetics and Pharmacodynamics of Anti-CD3 Monoclonal Antibody, Otelixizumab, in Subjects with Diabetes and Psoriasis | 3/12/2010 7:21:29 AM | Poster: Applications- Biologicals/vaccines |
A comparison of two model-based approaches to investigating covariate effects on the dose-exposure relationship in a Phase III context | 3/12/2010 2:43:04 PM | Poster: Methodology- Other topics | |
Investigation of the Influence of CYP3A4 Inhibition and Renal Impairment on Morphine and M6G Formation after Codeine Administration using Coupled Whole-Body PBPK Modelling | 3/15/2010 5:04:50 PM | Oral presentation: Physiology-based modelling | |
C. Woloch (1), J. Ciccolini (1), A. Di Paolo(2), A. Iliadis (1) | Population Pharmacokinetics of 5FU and its Major Metabolite 5-FDHU in Colorectal Cancer Patients | 3/15/2010 7:03:15 PM | Poster: Applications- Oncology |
Population Pharmacokinetics of Liposomal Amphotericin B, Caspofungin and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients | 4/11/2010 10:49:47 AM | Poster: Applications- Oncology | |
A Casual Graphic Goodness-of-fit Assessment for Markov Pharmacodynamic Models | 3/12/2010 10:06:31 PM | Poster: Methodology- Model evaluation | |
A population pharmacokinetic/pharmacodynamic model for duloxetine in diabetic peripheral neuropathy, plus methods for handling missing data. | 3/5/2010 10:23:30 AM | Poster: Applications- CNS | |
Zamuner S. (1), Paronetto M. (1), Moscardo E. (2), Renzulli C. (3), Terron A. (2), Poggesi I. (1) | The assessment of convulsion risk: a translational PK/PD modelling approach | 3/15/2010 5:15:25 PM | Poster: Applications- CNS |
Population Pharmacokinetics of Lopinavir/Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Children | 3/11/2010 5:30:47 PM | Oral Presentation: Clinical Applications | |
Evaluating the Extent of Chemotherapeutic Contamination from Central Venous Catheters in Children with Cancer and Providing Guidance for Accurate Reporting of PK Parameters | 3/15/2010 12:48:17 AM | Poster: Applications- Oncology | |
Effect of Various Meals on the Population Pharmacokinetics of Rifapentine | 3/11/2010 4:54:17 PM | Poster: Applications- Anti-infectives |
